Loading…
Employees: 2,735
Size HPGC Renmintongtai Pharmaceutical (600829.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $753M, the 2897th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.66 on 6 Nov 2026.
Performance Over six months the shares fell 10.9%, against -15.8% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 4.3% over the last twelve months (peer median +4.7%); the operating margin is 2.5% (peer median 11.0%).
Valuation It trades at 0.6× enterprise value to sales against a peer median of 2.5× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.6B | CN¥10.3B | CN¥10.0B | CN¥10.4B | CN¥9.61B |
| Revenue growth | — | +3% | -3% | +8% | — |
| Gross profit | CN¥879M | CN¥766M | CN¥779M | CN¥909M | CN¥829M |
| EBITDA | n/a | CN¥286M | CN¥363M | CN¥474M | CN¥450M |
| Net income | CN¥159M | CN¥134M | CN¥213M | CN¥292M | CN¥264M |
| Free cash flow | CN¥155M | CN¥283M | CN¥107M | CN¥310M | CN¥301M |
| Capital expenditure | CN¥28.3M | CN¥17.2M | CN¥8.04M | CN¥23.5M | CN¥6.42M |
| Total debt | CN¥1.91B | CN¥2.10B | CN¥2.33B | CN¥2.33B | CN¥2.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600829.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.4% | -5.3% | 9th lowest of 20 |
| 6-month return | -10.9% | -15.8% | 9th highest of 20 |
| Distance from 52-week high | -52.2% | -34.3% | 4th lowest of 20 |
| Revenue growth (TTM) | +4.3% | +4.7% | 9th lowest of 18 |
| Operating margin | 2.5% | 11.0% | 7th lowest of 18 |
| EV / Sales | 0.6× | 2.5× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 4.9% | -1.1% | 3rd most demanding of 10 |
| Growth delivered (Del g) | +5.3% | +11.3% | 4th lowest of 10 |
| Hurdle (Req g minus delivered) | -0.4 pp | -4.6 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | +0.2 pp | +2.3 pp | 8th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | 0.6× | 4.9% | +5.3% |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 7.3× | 33.8% | +19.8% |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 2.5× | -1.1% | +22.1% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | 0.4× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 2.7× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | 3.5× | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 1.5× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 8.7× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | 1.7× | -7.5% | -2.8% |